ClinicaliQ Trial Snapshot
- Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — Recruiting • Phase I • Oncology • NCT06980116.
- What is being tested: EXS73565 is an oral investigational agent being evaluated for safety, tolerability, pharmacokinetics, and antitumor activity in a dose-determining study in patients with relapsed or refractory B-cell malignancies.
- Patient eligibility overview: The trial enrolls adult patients with B-cell malignancies that have progressed despite or become resistant to prior standard treatments, representing a population with limited therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Eligibility Snapshot
- Key Inclusion Criteria: * Age ≥18 years at the time of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia. * Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.